Axogen: Deal Adds NerveTape Device for Sutureless Peripheral Nerve Repair >AXGN
Story updates
10:09:43 AM UTC
SquawkNews
The acquisition brings the first FDA-approved sutureless nerve repair device, expanding the addressable market and expected to be accretive to revenue, EBITDA margin, and EPS in the first year post-closing. The deal is set to close in Q4 2026, pending customary conditions.Original document: Axogen…
10:16:56 AM UTC
SquawkNews
By Colin KellaherAxogen has struck a deal to buy BioCircuit Technologies, the privately held maker of the NerveTape device for sutureless nerve repair, for $200 million in cash.Axogen on Thursday said it will fund the acquisition with proceeds from a public offering of 4.91 million shares at $42.50…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.